Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment

Gustave Roussy, Cancer Campus, Grand Paris1 site in 1 country100 target enrollmentJuly 9, 2009

ConditionsCarcinomas

InterventionsEscitalopram

DrugsEscitalopram

Overview

Phase: Phase 3
Intervention: Escitalopram
Conditions: Carcinomas
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Enrollment: 100
Locations: 1
Primary Endpoint: Evaluation of the effectiveness of escitalopram on depressive symptoms after 3 months
Last Updated: 16 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Evaluation of the effectiveness of escitalopram on depressive symptoms after 3 months in patients with head and neck squamous cell carcinomas (oral cavity, larynx, oropharynx and hypopharynx) and with an HADS total score > 11

Registry

clinicaltrials.gov

Start Date

July 9, 2009

End Date

TBD

Last Updated

16 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Eligibility Criteria

Inclusion Criteria

•Head and neck squamous cell carcinomas, stage I to IVb
•First-line curative cancer therapy : surgery and/or brachytherapy and/or chemotherapy
•HADS- T \>11
•Aged 18 to 75 yo, written consent required